Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab

BACKGROUND: Current therapy for allergic bronchopulmonary aspergillosis (ABPA) uses oral corticosteroids, exposing patients to the adverse effects of these agents. There are reports of the steroid-sparing effect of anti-IgE therapy with omalizumab for ABPA in patients with cystic fibrosis (CF), but...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Jennifer, deVos, Gabriele, Hudes, Golda, Rosenstreich, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508546/
https://www.ncbi.nlm.nih.gov/pubmed/23204847
http://dx.doi.org/10.2147/JAA.S34579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508546/
https://www.ncbi.nlm.nih.gov/pubmed/23204847
http://dx.doi.org/10.2147/JAA.S34579

Ejemplares similares